Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Advanced Solid Tumors With FGFR3 Mutation Clear all

Active, not recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552

View directory record Official record

Conditions: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions: TYRA-300; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more

Source: ClinicalTrials.gov public record

Updated Jan 11, 2026 · Synced May 22, 2026, 2:45 AM EDT

Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920

View directory record Official record

Conditions: Solid Tumor
Interventions: Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D); Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older

Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more

Source: ClinicalTrials.gov public record

Updated Jun 4, 2023 · Synced May 22, 2026, 2:45 AM EDT

Completed Phase 2 Interventional Results available

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998

View directory record Official record

Conditions: Malignant Neoplasm
Interventions: ponatinib hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Sameek Roychowdhury; Other
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Mar 23, 2025 · Synced May 22, 2026, 2:45 AM EDT

Completed Phase 1 Interventional

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

NCT01004224

View directory record Official record

Conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions: BGJ398; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Source: ClinicalTrials.gov public record

Updated Oct 3, 2019 · Synced May 22, 2026, 2:45 AM EDT

Recruiting Phase 1 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT06915753

View directory record Official record

Conditions: Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma
Interventions: TYRA-430; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Source: ClinicalTrials.gov public record

Updated Nov 19, 2025 · Synced May 22, 2026, 2:45 AM EDT

Withdrawn Phase 1Phase 2 Interventional

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NCT05222165

View directory record Official record

Conditions: Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions: Infigratinib; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 3 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Feb 22, 2023 · Synced May 22, 2026, 2:45 AM EDT